🖼
Figure 2. — Safety and efficacy of ravulizumab in patients with NMOSD previously treated wit
active
paper figure
Created: 2026-04-21T18:29:40
By: paper_figures_tool
Quality:
50%
🔗 External
ID: paper-fig-paper-41782198-2
Figure 2.Figure 2
Kaplan-Meier curve for time to first TESAE of infections and infestations in RTX-exposed vs RTX-Naïve patients. Kaplan-Meier estimates were calculated to evaluate the time to first TESAE of infections and infestations in patients treated with ravulizumab, stratified by prior RTX exposure. Patients who did not experience a TESAE of infections and infestations were censored at the earliest date of study completion, discontinuation date, last assessment date, death date, and data cutoff date. RTX, rituximab; TESAE, treatment-emergent serious adverse event.
▸Metadata
| pmid | paper-41782198 |
| caption | Kaplan-Meier curve for time to first TESAE of infections and infestations in RTX-exposed vs RTX-Naïve patients. Kaplan-Meier estimates were calculated to evaluate the time to first TESAE of infections |
| image_url | https://www.ebi.ac.uk/europepmc/articles/PMC13036264/bin/10.1177_13524585261425076-fig2.jpg |
| paper_title | Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial. |
| figure_label | Figure 2. |
| figure_number | 2 |
| _schema_version | 1 |
| source_strategy | pmc_api |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.